Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells.

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Blood

• Publication date

  1989-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD.V74.5.1747.BLOODJOURNAL7451747PMID 2506950
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hairy cell leukaemia: effects of phorbol ester on cell morphology and adherence and comparison with other B-cell neoplasias.

  2009cited by this paper
• Immunomodulating properties of a novel series of protein kinase C activators. The bryostatins.

  1988cited by this paper
• Regulation of hematopoiesis-IV: The role of interleukin-3 and bryostatin 1 in the growth of erythropoietic progenitors from normal and anemic W/Wv mice.

  1988cited by this paper
• Expression of tartrate‐resistant acid phosphatase in B‐CLL treated with phorbol ester or phorbol ester plus calcium ionophore

  1988cited by this paper
• Bryostatin 1, an activator of protein kinase C, mimics as well as inhibits biological effects of the phorbol ester TPA in vivo and in vitro.

  1988cited by this paper
• Triggering of neoplastic B cells via surface IgM and the cell surface antigens CD20 and CDw40. Responses differ from normal blood B cells and are restricted to certain morphologic subsets

  1988cited by this paper
• Protein kinase C as the receptor for the phorbol ester tumor promoters: sixth Rhoads memorial award lecture.

  1988cited by this paper
• Roles of G protein subunits in transmembrane signalling

  1988cited by this paper
• Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells.

  1988cited by this paper
• Activation of human T lymphocytes by bryostatin.

  1988cited by this paper
• Cell cycle progression of B-chronic lymphocytic leukemia cells induced to differentiate by TPA.

  1988cited by this paper
• Mimicry of bryostatin 1 induced phosphorylation patterns in HL-60 cells by high-phorbol ester concentrations.

  1988cited by this paper
• An assessment of phosphoinositide hydrolysis in antigenic signal transduction in lymphocytes.

  1988cited by this paper
• Analysis of signal transduction in B chronic lymphocytic leukemia cells.

  1988cited by this paper
• Phosphorylation of lamin B at the nuclear membrane by activated protein kinase C.

  1988cited by this paper
• G protein regulation of receptor signalling.

  1988cited by this paper
• Double and triple staining methods for studying the proliferative activity of human B and T lymphoid cells.

  1988cited by this paper
• Differing modulation of protein kinase C by bryostatin 1 and phorbol esters in JB6 mouse epidermal cells.

  1988cited by this paper
• Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C.

  1988cited by this paper
• Malignant chronic lymphocytic leukemia B cells express interleukin 2 receptors but fail to respond to interleukin 2's proliferative signal.

  1987cited by this paper
• Co-induction of lymphokine synthesis by the antineoplastic bryostatins.

  1987cited by this paper
• Partial parallelism and partial blockade by bryostatin 1 of effects of phorbol ester tumor promoters on primary mouse epidermal cells.

  1987cited by this paper
• Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin.

  1987cited by this paper
• Synergistic action of calcium ionophore A23187 and phorbol ester TPA on B-chronic lymphocytic leukemia cells.

  1987cited by this paper
• The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system.

  1987cited by this paper
• Inhibition by bryostatin 1 of the phorbol ester-induced blockage of differentiation in hexamethylene bisacetamide-treated Friend erythroleukemia cells.

  1987cited by this paper
• Differential effects of various protein kinase C activators on protein phosphorylation in human acute myeloblastic leukemia cell line KG-1 and its phorbol ester-resistant subline KG-1a.

  1987cited by this paper
• Phenotypic modulation of chronic lymphocytic, prolymphocytic, and lymphoplasmacytic leukemia cells by TPA: induction of TRAP isoenzyme 5 and HD6 (CD22) antigen and enhancement of IgM messenger RNA.

  1987cited by this paper
• Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells.

  1987cited by this paper
• Multiple, distinct forms of bovine and human protein kinase C suggest diversity in cellular signaling pathways.

  1986cited by this paper
• Signal transduction and intracellular events in T-lymphocyte activation.

  1986cited by this paper
• Morphological and isoenzymatic differentiation of B-chronic lymphocytic leukaemia cells induced by phorbolester.

  1986cited by this paper
• Impaired expression of cell surface receptors for B cell growth factor by chronic lymphocytic leukemia B cells.

  1986cited by this paper
• Studies and perspectives of protein kinase C.

  1986cited by this paper
• Cloning and expression of multiple protein kinase C cDNAs.

  1986cited by this paper
• Three activators of protein kinase C, bryostatins, dioleins, and phorbol esters, show differing specificities of action on GH4 pituitary cells.

  1986cited by this paper
• Heterogeneity of responsiveness of chronic lymphocytic leukemic B cells to B cell growth factor or interleukin 2

  1986cited by this paper
• Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60.

  1986cited by this paper
• The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia

  1986cited by this paper
• Induction of features characteristic of hairy cell leukemia in chronic lymphocytic leukemia and prolymphocytic leukemia cells.

  1986cited by this paper
• Leukemia diagnosis and testing of complement-fixing antibodies for bone marrow purging in acute lymphoid leukemia.

  1986cited by this paper
• Bryostatin, a non-phorbol macrocyclic lactone, activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor.

  1985cited by this paper
• Bryostatins: potent, new mitogens that mimic phorbol ester tumor promoters.

  1985cited by this paper
• The biochemical basis of transmembrane signalling by B lymphocyte surface immunoglobulin.

  1985cited by this paper
• Phenotypic modulation of chronic lymphocytic leukemia cells by phorbol ester: induction of IgM secretion and changes in the expression of B cell-associated surface antigens.

  1984cited by this paper
• Lineage relationship of chronic lymphocytic leukemia and hairy cell leukemia: studies with TPA.

  1984cited by this paper
• The role of protein kinase C in cell surface signal transduction and tumour promotion

  1984cited by this paper
• Differentiation of chronic lymphocytic leukemia cells after in vitro treatment with epstein‐barr virus or phorbol ester. I. Immunologic and morphologic studies

  1984cited by this paper
• Isolation and structure of bryostatin 1

  1982cited by this paper
• Heterogeneity of the response of chronic lymphocytic leukemia cells to phorbol ester.

  1982cited by this paper
• Phorbol ester-induced differentiation of chronic lymphocytic leukaemia cells

  1980cited by this paper
• Antineoplastic Components of Marine Animals

  1970cited by this paper

• Anticancer Activity of the Marine-Derived Compound Bryostatin 1: Preclinical and Clinical Evaluation

  2025cites this paper
• Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence

  2019cites this paper
• Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression.

  2017cites this paper
• 8 Pathophysiology of Protein Kinase C Isozymes in Chronic Lymphocytic Leukaemia

  2017cites this paper
• Enzastaurin: A lesson in drug development.

  2017cites this paper
• The expression of SLAMF7 levels in malignant B cells: a novel therapeutic pathway for patients with CLL

  2015influential citation
• Protein kinase C in cellular transformation: a valid target for therapy?

  2014cites this paper
• Variable induction of PRDM1 and differentiation in chronic lymphocytic leukemia is associated with anergy.

  2014cites this paper
• Pathophysiology of Protein Kinase C Isozymes in Chronic Lymphocytic Leukaemia

  2012cites this paper
• Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF.

  2011cites this paper
• Fine tuning of protein kinase C (PKC) isoforms in cancer: shortening the distance from the laboratory to the bedside.

  2011cites this paper
• The role of apoptosis in cancer development and treatment: focusing on the development and treatment of hematologic malignancies.

  2010cites this paper
• Perspectives of protein kinase C (PKC) inhibitors as anti-cancer agents.

  2009cites this paper
• Phase II study of bryostatin 1 and vincristine for aggressive non‐Hodgkin lymphoma relapsing after an autologous stem cell transplant

  2009cites this paper
• Potential role of PKC inhibitors in the treatment of hematological malignancies.

  2008cites this paper
• Molecular events as targets of anticancer drug therapy

  2008cites this paper
• The therapeutic role of targeting protein kinase C in solid and hematologic malignancies

  2007cites this paper
• Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) Lymphoma

  2006cites this paper
• Elucidating the role of protein kinase C in chronic lymphocytic leukaemia

  2006cites this paper
• Cell death signalling pathways in the pathogenesis and therapy of haematologic malignancies: overview of therapeutic approaches.

  2006cites this paper
• Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia

  2005cites this paper
• Effect of Serum and Antioxidants on the Immunogenicity of Protein Kinase C-Activated Chronic Lymphocytic Leukemia Cells

  2005cites this paper
• Different biological effects of the two protein kinase C activators bryostatin-1 and TPA on human carcinoma cell lines

  2004cites this paper
• Advances in chemotherapy for chronic lymphocytic leukemia.

  2004cites this paper
• Marine-derived anticancer agents in clinical trials

  2003cites this paper
• STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1.

  2003cites this paper
• Regulation of hairy-cell survival through constitutive activation of mitogen-activated protein kinase pathways

  2003cites this paper
• Bryostatin-1: A Novel PKC Inhibitor in Clinical Development

  2003cites this paper
• CHAPTER 12 – BIOSYNTHETIC PRODUCTS FOR ANTICANCER DRUG DESIGN AND TREATMENT: THE BRYOSTATINS

  2002cites this paper
• B‐chronic lymphocytic leukemia: practical aspects

  2002cites this paper
• REVIEW ARTICLE B-CHRONIC LYMPHOCYTIC LEUKEMIA: PRACTICAL ASPECTS

  2002cites this paper
• Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia

  2002cites this paper
• Specific cell-signal targets for cancer chemotherapy

  2002cites this paper
• Phase I study of bryostatin-1 and fludarabine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.

  2002cites this paper
• Bryostatin 1 induces differentiation and potentiates the antitumor effect of Auristatin PE in a human pancreatic tumor (PANC-1) xenograft model

  2001cites this paper
• Cladribine in the Treatment of Chronic Lymphocytic Leukemia

  2001cites this paper
• Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report.

  2000cites this paper
• Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine.

  1999cites this paper
• Pharmacology and clinical experience with bryostatin 1: a novel anticancer drug.

  1999cites this paper
• Infrared spectroscopic study of bryostatin 1-induced membrane alterations in a B-CLL cell line

  1999cites this paper
• Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

  1998cites this paper
• Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals.

  1998cites this paper
• Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.

  1998influential citation
• Establishment of a human pancreatic tumor xenograft model: potential application for preclinical evaluation of novel therapeutic agents.

  1998cites this paper
• Similarities between the sensitivity to 2-chlorodeoxyadenosine of lymphocytes from CLL patients and bryostatin 1-treated WSU-CLL cells: an infrared spectroscopic study.

  1998cites this paper
• Potentiation of 2-Chlorodeoxyadenosine Activity by Bryostatin 1 in the Resistant Chronic Lymphocytic Leukemia Cell Line (WSU-CLL): Association with Increased Ratios of dCK/5'-NT and Bax/Bcl-2

  1998cites this paper
• Bryostatin 1 (bryo1)-induced monocytic differentiation in THP-1 human leukemia cells is associated with enhanced c-fyn tyrosine kinase and M-CSF receptors.

  1997cites this paper
• Modulation of the expression of Bcl-2 and related proteins in human leukemia cells by protein kinase C activators: relationship to effects on 1-[β-D-arabinofuranosyl]cytosine-induced apoptosis

  1997cites this paper
• Modulation of ara-C induced apoptosis in leukemia by the PKC activator bryostatin 1.

  1997cites this paper
• Perspectives on purine analogues.

  1996cites this paper
• Early response gene signalling in bryostatin-stimulated primary B chronic lymphocytic leukaemia cells in vitro.

  1996cites this paper
• Modulation of protein kinase C activity and calcium-sensitive isoform expression in human myeloid leukemia cells by bryostatin 1: relationship to differentiation and ara-C-induced apoptosis.

  1996cites this paper
• Bryostatin 1 induces ubiquitin COOH-terminal hydrolase in acute lymphoblastic leukemia cells.

  1996cites this paper
• Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C.

  1996cites this paper
• Theory of the Origin, Function, and Evolution Secondary Metabolites*

  1995cites this paper
• The protein kinase C activator Bryostatin-1 induces the rapid release of TNF alpha from MONO-MAC-6 cells.

  1995cites this paper
• Effects of bryostatin-5 and hematopoietic growth factors on acute myeloid leukemia cell differentiation, proliferation, and primary plating efficiency.

  1995cites this paper
• Potential for protein kinase C inhibitors in cancer therapy.

  1995cites this paper
• Induced expression of alpha-enolase in differentiated diffuse large cell lymphoma.

  1994cites this paper
• Effects of phenylacetate on cells from patients with B-chronic lymphocytic leukemia.

  1994cites this paper
• Successful treatment of human Waldenström's macroglobulinemia with combination biological and chemotherapy agents.

  1994cites this paper
• Studies on bcl‐2 protein in cultured lymphoid cells.

  1994cites this paper
• Bryostatin 1: will the oceans provide a cancer cure?

  1993cites this paper
• Bryostatin 1‐Induced Modulation of the Acute Lymphoblastic Leukemia Cell Line Reh

  1993cites this paper
• In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity.

  1993cites this paper
• Differential effects of bryostatin 1 on human non-Hodgkin's B-lymphoma cell lines.

  1993cites this paper
• Modulation of gene expression in the acute promyelocytic leukemia cell line NB4.

  1993cites this paper
• Antitumor and Cytotoxic Compounds from Marine Organisms

  1993cites this paper
• Induction of differentiation of B-cell leukemia cell lines JVM-2 and EHEB by bryostatin 1.

  1993cites this paper
• Effects of dolastatins on human B-lymphocytic leukemia cell lines.

  1993cites this paper
• Differentiation and growth modulation of myeloid leukemia cells by the protein kinase C activating agent bryostatin-1.

  1993cites this paper
• Bryostatin 1-induced hairy cell features on chronic lymphocytic leukemia cells in vitro.

  1993cites this paper
• Dolastatin 10 and dolastatin 15: effects of two natural peptides on growth and differentiation of leukemia cells.

  1992cites this paper
• Structural modifications of bryostatin 2.

  1992cites this paper
• Pharmacology of second messengers: a critical appraisal.

  1992cites this paper
• In vivo administration of bryostatin 1, a protein kinase C activator, decreases murine resistance to Salmonella typhimurium.

  1992cites this paper
• Isolation and structure of bryostatins 14 and 15

  1991cites this paper
• 1H and 13C NMR assignments of the antitumor macrolide bryostatin 1

  1991cites this paper
• Effect of pharmacologic manipulation of protein kinase C by phorbol dibutyrate and bryostatin 1 on the clonogenic response of human granulocyte‐macrophage progenitors to recombinant GM‐CSF

  1991cites this paper
• In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-beta-D-arabinofuranosylcytosine in human leukemia cells.

  1991cites this paper
• Expression of proto-oncogene c-jun during differentiation of B-chronic lymphocytic leukemia.

  1990cites this paper
• Drug molecules of marine origin.

  1990cites this paper
• In vitro beta 2-microglobulin (beta 2m) secretion by normal and leukaemic B-cells: effects of recombinant cytokines and evidence for a differential response to the combined stimulus of phorbol ester and calcium ionophore.

  1990cites this paper
• Down‐regulation of CD5 mRNA in B‐chronic lymphocytic leukemia cells by differentiation‐inducing agents

  1990cites this paper
• Antineoplastic agents, 195. Isolation and structure of aceratioside from Aceratium megalospermum.

  1990cites this paper
• Differential expression of TRAP Isoenzyme in B-CLL Cells Treated with Different Inducers.

  1990cites this paper
• Differential responses of B-CLL clones to in vitro stimulation with cytokines.

  1990cites this paper